Hydrix Secures A$3.4M Contract to Advance Remedy Robotics’ N1 Medical Platform

Hydrix Expands Role in Advanced Medical Robotics

Hydrix Limited (ASX:HYD) has secured a substantial A$3.4 million engineering contract with San Francisco-based Remedy Robotics, a company pushing the boundaries of AI-enabled endovascular robotic intervention. The deal significantly broadens Hydrix’s existing partnership, reinforcing its position as a specialist in safety-critical software and embedded electronics within the fast-growing medical robotics sector.

The contract is set to generate revenue progressively over the 2027 financial year and represents more than half of Hydrix’s current market capitalisation, underscoring its materiality for the company’s near-term financials.

Supporting the N1 System for Remote Cardiovascular Care

Remedy Robotics’ N1 System aims to transform cardiovascular intervention by enabling complex endovascular procedures to be performed remotely with precision, leveraging robotics, AI, and advanced computer vision. This technology targets a pressing healthcare challenge: expanding access to specialist stroke and cardiovascular treatments beyond metropolitan centres.

Hydrix’s role encompasses developing safety-critical software, embedded electronics, and verification-ready hardware inputs, accelerating the N1 platform towards future clinical trials. Remedy’s CEO Dr David Bell highlighted the importance of Hydrix’s multidisciplinary expertise in regulated medical device development as critical to advancing their vision of flawless, immediate intervention regardless of patient location.

Strategic Significance Amid Hydrix’s Growth Trajectory

Hydrix Managing Director Gavin Coote emphasised the deepening trust Remedy places in Hydrix’s engineering capabilities, which span complex regulated medical technologies and AI-enabled systems. This contract aligns with Hydrix’s broader international expansion strategy focused on mission-critical medical technologies, including Class II and III medical devices.

Given the contract’s size relative to Hydrix’s market cap, it signals a meaningful revenue boost following a period of capital raising and debt management earlier this year. Hydrix recently completed an entitlement offer raising over $5 million and has been actively converting convertible notes to strengthen its balance sheet, moves that complement its push into advanced medical and defence technologies.

Medical Robotics Market Outlook

The US advanced medical robotics market was valued at US$3.84 billion in 2025, with forecasts projecting a 13.1% compound annual growth rate through 2033, according to Grand View Research. Hydrix’s contract with Remedy positions it well to capitalise on this expanding sector, especially as demand grows for AI-enabled robotic platforms that enhance precision and accessibility in medical interventions.

Remedy Robotics holds 48 patents, including foundational machine learning patents applied to surgical robotics, and maintains partnerships with leading clinicians worldwide, including through the Australian Stroke Alliance. This network may provide Hydrix with further opportunities to extend its footprint in cutting-edge medical device development.